Company: PSTV
Filing Date: 2025-06-20
Form Type: 8-K
Source: 0001193125-25-143665
Chunk: 4

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-06-20
Form: 8-K
Item: Item 1.01
Chunk 4
---
 the Registration Rights Agreement contain customary representations, warranties, conditions and indemnification obligations of the parties. The Company has the right to terminate the Purchase Agreement at any time, at no cost or penalty. During any “event of suspension” under the Purchase Agreement, Lincoln Park does not have the right to terminate the Purchase Agreement; however, the Company may not initiate any regular or other purchase of shares by Lincoln Park, until such event of suspension is cured. In addition, in the event of bankruptcy proceedings by or against the Company, the Purchase Agreement will automatically terminate.

The foregoing descriptions of the Purchase Agreement and the Registration Rights Agreement are qualified in their entirety by reference to the full text of such agreements, copies of which are attached hereto as Exhibits 10.1 and 10.2, respectively, and each of which is incorporated herein in its entirety by reference. The representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties.

  Item 3.02.      Unregistered Sales of Equity Securities.  

The information contained above in Item 1.01 is hereby incorporated by reference into this Item 3.02.

In the Purchase Agreement, Lincoln Park represented to the Company, among other things, that it is an “accredited investor” (as such term is defined in Rule 501(a) of Regulation D under the Securities Act of 1933, as amended (the “ Securities Act”)). The securities referred to in this current report on Form8-Kare being issued and sold by the Company to Lincoln Park in reliance upon the exemptions from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder.

  Item 9.01      Financial Statements and Exhibits.  

(d) Exhibits.

  Exhibit      Description                                                                                                                    
                                                                                                                                              
   Number                                                                                                                                     
     10.1      Purchase Agreement, dated June 18, 2025, by and between Plus Therapeutics, Inc. and Lincoln Park Capital Fund, LLC             
     10.2      Registration Rights Agreement, dated June 18, 2025, by and between Plus Therapeutics, Inc. and Lincoln Park Capital Fund, LLC  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────